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Mitochondria are found in all nucleated human cells and perform various essential 
functions, including the generation of cellular energy. Mitochondria are under dual 
genome control. Only a small fraction of their proteins are encoded by mitochondrial 
DNA (mtDNA), whereas more than 99% of them are encoded by nuclear DNA (nDNA). 
Mutations in mtDNA or mitochondria-related nDNA genes result in mitochondrial dys-
function leading to insufficient energy production required to meet the needs for various 
organs, particularly those with high energy requirements, including the central nervous 
system, skeletal and cardiac muscles, kidneys, liver, and endocrine system. Because 
cardiac muscles are one of the high energy demanding tissues, cardiac involvement 
occurs in mitochondrial diseases with cardiomyopathies being one of the most frequent 
cardiac manifestations found in these disorders. Cardiomyopathy is estimated to occur 
in 20–40% of children with mitochondrial diseases. Mitochondrial cardiomyopathies 
can vary in severity from asymptomatic status to severe manifestations including heart 
failure, arrhythmias, and sudden cardiac death. Hypertrophic cardiomyopathy is the 
most common type; however, mitochondrial cardiomyopathies might also present as 
dilated, restrictive, left ventricular non-compaction, and histiocytoid cardiomyopathies. 
Cardiomyopathies are frequent manifestations of mitochondrial diseases associated 
with defects in electron transport chain complexes subunits and their assembly factors, 
mitochondrial transfer RNAs, ribosomal RNAs, ribosomal proteins, translation factors, 
mtDNA maintenance, and coenzyme Q10 synthesis. Other mitochondrial diseases with 
cardiomyopathies include Barth syndrome, Sengers syndrome, TMEM70-related mito-
chondrial complex V deficiency, and Friedreich ataxia.
Keywords: hypertrophic cardiomyopathy, dilated cardiomyopathy, restrictive cardiomyopathy, non-compaction 
cardiomyopathy, histiocytoid cardiomyopathies, Barth syndrome, Friedreich ataxia
iNTRODUCTiON
Metabolic disorders account for a minority of causes of cardiomyopathies. However, diagnosing a 
metabolic disease as a cause for cardiomyopathy can have prognostic and therapeutic implications. 
Major groups of metabolic disorders associated with cardiomyopathy include organic acidemias 
(e.g., propionic acidemia), fatty acid oxidation defects (e.g., very long chain acyl CoA dehydroge-
nases deficiency), lysosomal storage diseases (e.g., Fabry disease), glycogen storage diseases (e.g., 
Pompe disease), congenital disorders of glycosylation, and mitochondrial disorders (1).
Mitochondrial diseases are a clinically and genetically heterogeneous group of disorders that 
result from dysfunction of the mitochondrial respiratory chain, which is responsible for the genera-
tion of most cellular energy (2, 3). Because cardiac muscles are one of the high energy demanding 
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tissues, cardiac involvement occurs in large number of mito-
chondrial diseases. The most frequent cardiac manifestations of 
mitochondrial diseases are cardiomyopathies. Arrhythmias and 
conduction defects, pulmonary hypertension, pericardial effu-
sion, dilated aortic root, and coronary heart disease can also be 
seen in mitochondrial diseases (4, 5).
In this article, we review normal mitochondrial structure and 
function, pathogenesis of mitochondrial diseases, clinical aspects 
of mitochondrial cardiomyopathies, mitochondrial diseases 
frequently associated with cardiomyopathies, and diagnosis and 
management of mitochondrial cardiomyopathies.
NORMAL MiTOCHONDRiAL  
STRUCTURe AND FUNCTiON
Mitochondria are found in all nucleated human cells each of which 
typically contains in its cytoplasm several hundred mitochondria 
depending on the energy needs for the tissue. Mitochondria are 
composed of two bilayer membranes that create two distinct 
compartments: an intermembrane space and a matrix space 
within the inner membrane. The mitochondrial outer membrane 
is smooth, whereas the inner mitochondrial membrane is highly 
folded, forming structures called cristae. The large surface area 
of the inner mitochondrial membrane accommodates energy-
generating multipolypeptide enzyme complexes called respira-
tory chain or electron transport chain (ETC) complexes (2).
Approximately 1,500 proteins are involved in maintain-
ing mitochondrial structure and function; however, <1% are 
encoded by mitochondrial DNA (mtDNA), while more than 99% 
of mitochondrial proteins are encoded by nuclear DNA (nDNA). 
Therefore, mitochondria are under dual genome control. Each 
mitochondrion contains mtDNA in the form of a multicopy, 
16.6 kb circular double-stranded DNA. The mtDNA encodes 13 
essential polypeptides for the ETC complexes and 24 different 
RNAs, including 2 ribosomal RNAs (rRNAs) and 22 transfer 
RNAs (tRNAs) (3, 6). The remaining ETC complexes subunits, as 
well as proteins needed to assemble the ETC complexes (assembly 
factors), maintain mtDNA, and transport molecules across the 
mitochondrial membranes, are encoded by nDNA, synthesized 
on cytoplasmic ribosomes, and imported into mitochondria (7). 
Unlike nDNA, which replicates with each cell division, mtDNA 
replicates continuously and independently of cell division. Two 
nDNA-encoded enzymes play major roles in mtDNA replication: 
DNA polymerase gamma that functions in replication and repair 
of mtDNA, and the twinkle protein that serves the function 
of a DNA helicase that is required for mtDNA replication (8). 
Transcription of mtDNA produces a polycistronic precursor 
RNA that is then processed to produce individual mRNA, tRNA, 
and rRNA molecules. The nDNA-encoded mitochondrial RNA 
polymerase and mitochondrial transcriptions factors are needed 
for the mitochondrial transcription process (9). The mRNAs for 
the 13 mtDNA-encoded proteins are translated on mitochondrial 
ribosomes. Mitochondrial tRNAs and rRNAs are required for this 
process in addition to several nDNA-encoded proteins, including 
mitochondrial ribosomal proteins and mitochondrial translation 
factors (9). The nDNA-encoded mitochondrial polypeptides are 
synthesized on cytosolic ribosomes and transported into the 
mitochondria via mitochondrial protein import systems, includ-
ing the translocase of the outer membrane (TOM) and translocase 
of the inner membrane (TIM) complexes (7, 10).
Mitochondria perform various essential functions, including 
the generation of most of the energy needed by cells in the form 
of ATP in a process called oxidative phosphorylation (OXPHOS) 
carried out by the ETC complexes in the inner mitochondrial 
membrane. Complexes I, II, III, and IV make up the ETC, whereas 
complex V is the ATP synthase. Hydrogen atoms generated from 
different catabolic pathways bind to nicotinamide adenine dinu-
cleotide (NAD+) and flavin adenine dinucleotide (FAD) to yield 
NADH and FADH2, respectively. NADH is oxidized by complex 
I (NADH dehydrogenase), and the electrons are transported 
through flavin mononucleotide (FMN) and multiple iron–sulfur 
(Fe–S) centers in complex I until they are transferred to coenzyme 
Q10 (CoQ10). CoQ10 also accepts hydrogen atoms from FADH2 
generated by β-oxidation and the TCA enzyme succinate dehy-
drogenase (complex II). Electrons are subsequently transferred 
from CoQ10 to complex III (bc1 complex) within which the elec-
trons move through cytochrome b, cytochrome c1, and the Fe–S 
components. The electrons are then transferred from complex 
III to cytochrome c, which transfers the electrons to complex IV 
(cytochrome c oxidase). Within this complex, the electrons are 
transferred through copper centers and cytochromes a and a3 
and ultimately combine with O2 to generate H2O. The energy that 
is released during electron transfer is used to pump protons from 
inside the mitochondrial matrix across the inner mitochondrial 
membrane into the intermembrane space through complexes I, 
III, and IV. The resulting electrochemical gradient forces protons 
to move back through a proton channel in complex V (ATP syn-
thase), which utilizes this energy in synthesizing ATP. The ETC 
complexes are multipolypeptides encoded by both mtDNA and 
nDNA except for complex II, which is encoded entirely by nDNA 
(11) (Figure 1).
MiTOCHONDRiAL DYSFUNCTiON  
AND DiSeASeS
Mutations in mtDNA or mitochondria-related nDNA genes 
result in mitochondrial dysfunction leading to mitochondrial 
diseases (12). Defects in mtDNA can be either point muta-
tions or rearrangements. Point mutations in mtDNA can affect 
protein-encoding genes or genes encoding tRNA or rRNA. 
These mutations are maternally inherited and typically associ-
ated with very variable phenotypes. Rearrangements of mtDNA 
include deletions and duplications that differ in size and position 
but typically encompass several genes. These rearrangements 
are usually sporadic arising de novo but can be maternally 
inherited (13). Mutations in nDNA genes are inherited in an 
autosomal recessive, autosomal dominant, or X-linked manner. 
Mitochondrial dysfunction can result from mutations in nDNA 
genes encoding ETC complexes subunits or their assembly fac-
tors (11), mitochondrial import complexes (10), mitochondrial 
ribosomal proteins and translational factors (14), and CoQ10 
biosynthesis enzymes (15). The mtDNA is maintained by a group 
FiGURe 1 | A diagram showing electron transfer along the mitochondrial eTC complexes, hydrogen pumping across the inner mitochondrial 
membrane, and ATP synthesis.
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of nDNA-encoded proteins that function either in mitochondrial 
deoxyribonucleoside triphosphate (dNTP) synthesis or mtDNA 
replication. Mutations in any of these genes result in depletion 
of the mitochondrial dNTP pool or impaired mtDNA replica-
tion, leading to severe reduction in mtDNA content (mtDNA 
depletion). Inadequate amount of mtDNA results in impaired 
synthesis of key subunits of ETC complexes (16). Finally, Fe–S 
clusters are ubiquitous cofactors that are composed of iron and 
inorganic sulfur. These clusters are important prosthetic groups 
that are required for the function of proteins involved in various 
activities, including electron transport in ETC complexes. Defects 
in the process of Fe–S clusters can result in impaired ETC activity 
and mitochondrial dysfunction (17).
Defects in mtDNA- or nDNA-encoded mitochondrial proteins 
result in mitochondrial respiratory chain dysfunction leading to 
impaired OXPHOS and inability to generate sufficient energy to 
meet the needs for various organs, particularly those with high 
energy demand, including the central nervous system, skeletal 
and cardiac muscles, kidneys, liver, and endocrine system (2, 3). 
Additionally, due to the impaired OXPHOS, NADH cannot be 
utilized and the NADH:NAD ratio increases, which results in 
the inhibition of the TCA cycle. Pyruvate, produced through 
glycolysis, is increased due to the TCA cycle inhibition. Both 
elevated pyruvate and NADH:NAD ratio result in shifting the 
equilibrium of lactate dehydrogenase toward the production of 
lactate from pyruvate. Lactate can accumulate, causing systemic 
acidosis. Lactic acidosis is among one of the common features of 
mitochondrial disorders (6).
In addition to ATP deficiency, consequences of mitochondrial 
dysfunction include aberrant calcium handling, excessive reac-
tive oxygen species (ROS) production, apoptosis dysregulation, 
and nitric oxide (NO) deficiency all of which contribute to the 
pathogenesis of mitochondrial diseases (18). During OXPHOS, 
a small part of oxygen is partially reduced and converted to 
ROS (superoxide and hydrogen peroxide). Under normal 
conditions, ROS can be scavenged by various enzymes, includ-
ing the mitochondrial superoxide dismutase and glutathione 
peroxidase (19,  20). ROS, whose generation is enhanced as a 
result of OXPHOS blockade, can irreversibly modify many 
cellular macromolecules leading to cellular toxicity. Increased 
ROS production in mitochondrial diseases can result in protein, 
lipid, and DNA damage, which can potentially lead to further 
cellular damage and dysfunction (19, 20). One of the mitochon-
drial functions is calcium buffering. In addition, mitochondrial 
ATP production is needed to fuel calcium pumps in the plasma 
membrane and endoplasmic reticulum. Therefore, mitochondrial 
dysfunction can result in aberrant calcium handling. This model 
could contribute to the frequent involvement of muscle and nerve 
tissues in mitochondrial diseases, since these cells rely heavily on 
ATP and on fluctuating levels of intracellular calcium (21, 22). 
Mitochondria are also major regulators of apoptosis. In response 
to several intracellular stress conditions, supermolecular chan-
nels called mitochondrial permeability transition pores open 
resulting in increased mitochondrial inner membrane perme-
ability. Apoptosis is initiated when the inner mitochondrial mem-
brane becomes permeable leading to the release of several toxic 
mitochondrial proteins into the cytosol, including cytochrome c. 
These proteins activate latent forms of caspases, resulting in the 
execution of apoptosis. Therefore, excessive cell loss can contrib-
ute to the pathology in mitochondrial diseases (23). Finally, there 
is growing evidence that NO deficiency occurs in mitochondrial 
diseases and can play a major role in the pathogenesis of several 
complications observed in these diseases, including stroke-like 
episodes, myopathy, diabetes, and lactic acidosis. NO deficiency 
in mitochondrial disorders is multifactorial in origin, including 
impaired NO production and postproduction sequestration (24).
The mtDNA in cells can be identical (homoplasmy) or a 
mixture of two or more types (heteroplasmy). Some mtDNA 
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mutations affect all copies of the mtDNA (homoplasmic muta-
tions), while most of the mutations are present in only some cop-
ies of mtDNA and cells harbor a mixture of mutant and normal 
mtDNA (heteroplasmic mutations) (25). When cell divides, the 
mitochondria are distributed in a stochastic process in daughter 
cells. Therefore, when a cell harboring a heteroplasmic mtDNA 
mutation divides, it is a matter of chance whether the mutant 
mtDNAs will be partitioned into one daughter cell or another. 
Therefore, over time, the percentage of mutant mtDNAs can 
differ in different tissues and organs. This process, which is 
called replicative segregation, explains why the heteroplasmy 
percentage of mutant mtDNA may vary among organs and tissues 
within the same individual. The different tissues and organs rely 
on mitochondrial energy to different extents. As the percentage 
of mutated mtDNA increases, energy production declines. When 
the proportion of mutant mtDNA crosses a critical threshold level, 
the impaired energy production will result in organ dysfunction 
and clinical manifestations. The threshold level varies among dif-
ferent organs and tissues depending on their energy requirement 
(26). The replicative segregation and different organ threshold 
levels can explain in part the varied clinical phenotypes observed 
in individuals with mtDNA mutations. On the other hand, the 
clinical phenotypes of nDNA-related mitochondrial diseases are 
typically more homogenous than the mtDNA-related disease, as 
all the mitochondria are similarly affected (3).
Mitochondrial disorders are not uncommon with a minimum 
prevalence of 1 in 5,000 (12). Mitochondria are essential compo-
nents of all nucleated cells. Therefore, mitochondrial dysfunction 
affects many organs, particularly those with high energy require-
ments. Insufficient energy for various organs results in multi-
organ dysfunction and the variable manifestations observed in 
mitochondrial diseases, including epilepsy, intellectual disability, 
skeletal and cardiac myopathies, hepatopathies, endocrinopa-
thies, and nephropathies (2, 3, 6). Although the vast majority 
of mitochondrial diseases involve multiple organ systems, some 
mitochondrial diseases may affect a single organ (e.g., Leber 
hereditary optic neuropathy, and non-syndromic sensorineural 
hearing loss) (2). Mitochondrial diseases can begin at any age. 
Many patients with mitochondrial diseases display a cluster of 
clinical features that fall into a discrete clinical syndrome such 
as Kearns–Sayre syndrome, mitochondrial encephalomyopathy 
with lactic acidosis and stroke-like episodes (MELAS), myoclonic 
epilepsy with ragged-red fibers (MERRF), neurogenic weakness 
with ataxia and retinitis pigmentosa (NARP), mitochondrial 
neurogastrointestinal encephalopathy (MNGIE), and Alpers 
syndrome. However, there is often considerable clinical variabil-
ity, and many affected individuals do not fit into one particular 
syndrome (2, 3, 6).
CLiNiCAL ASPeCTS OF MiTOCHONDRiAL 
CARDiOMYOPATHieS
Mitochondrial cardiomyopathy can be described as a myocardial 
disorder characterized by abnormal myocardial structure and/or 
function secondary to genetic defects resulting in the impairment 
of the mitochondrial respiratory chain, in the absence of con-
comitant coronary artery disease, hypertension, valvular disease, 
and congenital heart disease (27). Cardiomyopathy is estimated 
to occur in 20–40% of children with mitochondrial diseases 
(5,  28). Therefore, screening for cardiomyopathy is a standard 
part of the management of children and adults with known or 
suspected mitochondrial disease (29).
Mitochondrial cardiomyopathies can vary in severity 
from asymptomatic status to severe manifestations, including 
heart failure, arrhythmias, and sudden cardiac death. Cardiac 
manifestations can be precipitated or worsen during metabolic 
decompensation episodes that are often caused by stressors, 
such as febrile illnesses or surgery, and can be accompanied by 
acute heart failure (27). It has been reported that mortality in 
children with mitochondrial diseases is significantly higher 
in those with cardiomyopathy than in those without (28). The 
clinical manifestations of mitochondrial cardiomyopathies are 
often accompanied by other manifestations of the multi-organ 
involvement of mitochondrial diseases. On the other hand, mito-
chondrial cardiomyopathy can occur in the absence of known 
mitochondrial disease, of which it may be the first or the sole 
clinical manifestation (29).
Hypertrophic cardiomyopathy is the most common form; 
however, mitochondrial cardiomyopathies might also present 
as dilated, restrictive, left ventricular non-compaction, and his-
tiocytoid cardiomyopathies (4). Hypertrophic cardiomyopathy 
is the most frequent cardiac manifestation in mitochondrial 
diseases and can occur in more than 50% of individuals with 
mitochondrial cardiomyopathies (5). It can be detected as early 
as the antenatal period and may be the only manifestation of 
a mitochondrial disease or a part of a multi-organ disease. 
Obstructive hypertrophic cardiomyopathy rarely occurs, but 
hypertrophic cardiomyopathy frequently develops into systolic 
dysfunction followed by decompensation and dilatation of the 
left ventricle (30). Dilated cardiomyopathy, which can be primary 
or secondary following hypertrophic cardiomyopathy, occurs less 
frequently than hypertrophic cardiomyopathy, whereas restrictive 
cardiomyopathy is a rare manifestation of mitochondrial diseases 
(31). Although left ventricular non-compaction cardiomyopathy 
is also a rare finding in mitochondrial diseases, among indi-
viduals with non-compaction, mitochondrial diseases are highly 
prevalent. Left ventricular non-compaction cardiomyopathy is 
generally more frequent in males and tends to develop during 
pregnancy in females. Occasionally, it may disappear during the 
disease course in some individuals with mitochondrial diseases 
(32). Histiocytoid cardiomyopathy (Purkinje fiber dysplasia) is 
histologically characterized by morphological and functional 
abnormalities of cardiomyocytes and Purkinje cells with a 
cytoplasm like in histiocyte foam cells, which contain glycogen 
and lipids. It has been reported exclusively in individuals with 
mitochondrial diseases (33).
MiTOCHONDRiAL DiSeASeS 
FReQUeNTLY ASSOCiATeD wiTH 
CARDiOMYOPATHieS
Cardiomyopathies are frequent manifestations of mitochondrial 
diseases associated with defects in ETC complexes subunits and 
TABLe 1 | Mitochondrial diseases frequently associated with 
cardiomyopathies.
Mitochondrial 
diseases
Genes Clinical 
manifestations
eTC complexes deficiencies
Complex I  
deficiency
Subunit mtDNA genes: 
MTND1, MTND2, MTND4, 
MTND5, and MTND6
Subunit nDNA genes: 
NDUFV1, NDUFV2, 
NDUFS1, NDUFS2, 
NDUFS3, NDUFS4, 
NDUFS6, NDUFS7, 
NDUFS8, NDUFA2, 
NDUFA11, NDUFAF3, 
NDUFA10, NDUFB3, 
NDUFB9, and NDUFA1
Assembly genes: NDUFAF2, 
NDUFAF4, NDUFAF5, 
NUBPL, NDUFAF1, 
FOXRED1, and ACAD9
Hypertrophic 
cardiomyopathy
Growth failure
Developmental delay
Epilepsy
Ataxia
Weakness
Spasticity
Leukoencephalopathy
Macrocephaly
Sensorineural deafness
Hepatic dysfunction
Lactic acidosis
Hypoglycemia
Complex II  
deficiency
Subunit genes: SDHA and 
SDHD
Hypertrophic, dilated, 
and non-compaction 
cardiomyopathies
Growth failure
Developmental delay
Weakness
Spasticity
Ataxia
Epilepsy
Leukodystrophy
Contractures
Ophthalmoplegia
Pigmentary retinopathy
Optic atrophy
Lactic acidosis
Complex III  
deficiency
MTCYB Hypertrophic, dilated, 
and histiocytoid 
cardiomyopathies
Growth failure
Exercise intolerance
Optic atrophy
Stroke-like episodes
Epilepsy
Lactic acidosis
Hypoglycemia
Complex IV  
deficiency
Subunit mtDNA genes: 
MTCO1, MTCO2, and 
MTCO3
Dilated, hypertrophic, 
and histocytoid 
cardiomyopathies
Growth failure
Developmental delay
Ataxia
Epilepsy
Hypotonia
Subunit nDNA genes: 
COX6B1
Assembly factors: COX10, 
COX14, COX15, COX20, 
SCO1, SCO2, COA3, and 
COA5
Mitochondrial 
diseases
Genes Clinical 
manifestations
Sensorineural hearing 
loss
Optic atrophy
Pigmentary retinopathy
Liver dysfunction
Renal tubulopathy
Lactic acidosis
Mitochondrial tRNA genes
MERRF (myoclonic 
epilepsy with ragged-
red fibers) syndrome
MTTK Dilated and histiocytoid 
cardiomyopathy
Epilepsy
Ataxia
Weakness
Sensorineural hearing 
loss
Short stature
Lactic acidosis
MELAS 
(mitochondrial 
encephalomyopathy, 
lactic acidosis, and 
stroke-like episodes) 
syndrome
MTTL1 Hypertrophic 
cardiomyopathy
Muscle weakness
Stroke-like episodes
Dementia
Epielpsy
Sensorineural hearing 
loss
Lactic acidosis
Diabetes
Short stature
Mitochondrial DNA depletion
Mitochondrial 
neurogastrointestinal 
encephalopathy 
syndrome (MNGIE)
TYMP Hypertrophic 
cardiomyopathy
Gastrointestinal 
dysmotility
Cachexia
Ptosis
Ophthalmoplegia
Hearing loss
Peripheral neuropathy
Leukoencephalopathy
CoQ10 deficiency
Coenzyme Q10 
deficiency
COQ2, COQ4, COQ6, 
COQ7, COQ9, ADCK3, 
PDSS1, and PDSS2
Hypertrophic 
cardiomyopathy
Growth failure
Developmental delay
Weakness
Epilepsy
Ataxia
Pigmentary retinopathy
Sensorineural hearing 
loss
Liver dysfunction
Renal impairment
Pancytopenia
Lactic acidosis
(Continued)
(Continued)
5
El-Hattab and Scaglia Mitochondrial Cardiomyopathies
Frontiers in Cardiovascular Medicine | www.frontiersin.org July 2016 | Volume 3 | Article 25
their assembly factors, mitochondrial tRNAs, rRNAs, ribosomal 
proteins, translation factors, mtDNA maintenance, and CoQ10 
synthesis. Other mitochondrial diseases with cardiomyopathies 
include Barth syndrome and other 3-methylglutaconic aciduria 
disorders, and Friedreich ataxia (Table 1).
Complex I deficiency, which is clinically and genetically 
heterogeneous, can present with hypertrophic cardiomyo-
pathy that might be isolated or associated with multi-organ 
disease. Cardiomyopathy has been reported with mutations in 
TABLe 1 | Continued
Mitochondrial 
diseases
Genes Clinical 
manifestations
3-Methylglutaconic acidurias
3-Methylglutaconic 
aciduria type II (Barth 
syndrome)
TAZ Non-compaction, 
dilated, and hypertrophic 
cardiomyopathies
Growth failure
Weakness
Arrhythmias
Neutropenia
3-Methylglutaconic 
aciduria, type 
V (dilated 
cardiomyopathy and 
ataxia syndrome)
DNAJC19 Dilated and 
non-compaction 
cardiomyopathies
Growth failure
Ataxia
Testicular dysgenesis
Anemia
Mitochondrial 
complex V deficiency
TMEM70 Hypertrophic 
cardiomyopathy
Growth failure
Developmental delay
Hypotonia
Ataxia
Epilepsy
Leukodystrophy
Distinctive facial features
Lactic acidosis
Hyperammonemia
Sengers syndrome AGK Hypertrophic 
cardiomyopathy
Growth failure
Cataracts
Hypotonia
Weakness
Lactic acidosis
Defects in iron–sulfur cluster
Friedreich ataxia FXN
Hypertrophic 
cardiomyopathy
Ataxia
Dysarthria
Peripheral sensory 
neuropathy
Diabetes mellitus
TABLe 1 | Continued
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mitochondrial (e.g., MTND1 and MTND5) and nuclear (e.g., 
NDUFS2, NDUFV2, and NDUFA2) genes encoding complex 
I subunits, and nuclear genes that encode complex I assembly 
factors (e.g., ACAD9 and NDUFAF1) (34, 35). Complex II is 
entirely encoded by nDNA, and its deficiency has been reported 
in individuals with hypertrophic, dilated, and non-compaction 
cardiomyopathies who carried mutations in complex II subunits 
genes (SDHA and SDHD) (36, 37). Complex III deficiency can 
also cause cardiomyopathy that can either be isolated or accom-
panied with multi-organ involvement. Hypertrophic, dilated, and 
histiocytoid cardiomyopathies were reported in individuals with 
complex III deficiency and mutations in the MTCYB gene encod-
ing cytochrome b (38–40). Dilated, hypertrophic, and histocytoid 
cardiomyopathies have been reported in complex IV deficiencies 
associated with mutations in complex IV subunit genes (COX6B1, 
MTCO2, and MTCO3) and complex IV assembly factors genes 
(SURF1 and SCO2) (41, 42).
Mutations in several mitochondrial tRNA genes (e.g., 
MTTK causing MERRF syndrome and MTTL1 causing MELAS 
 syndrome) have been reported with multi-organ mitochondrial 
diseases or isolated cardiomyopathies. Cardiomyopathies associ-
ated with pathogenic variants in genes encoding mitochondrial 
tRNAs are usually hypertrophic, but can also be dilated or histio-
cytoid cardiomyopathy (29, 43). Hypertrophic cardiomyopathy 
has been reported with mutations in the mitochondrial 16S 
rRNA gene (MTRNR2) and restrictive cardiomyopathy with 
the m.1555A>G mutation in the mitochondrial 12S rRNA gene 
(MTRNR1) that is typically associated with aminoglycoside-
induced hearing loss (44, 45). Mutations in genes coding mitochon-
drial ribosomal proteins (e.g., MRPL3 and MRPL44) can cause 
hypertrophic cardiomyopathy accompanied by multi-organ disease 
(46, 47). Mutations in TSFM, encoding a mitochondrial transla-
tion elongation factor, can be associated with hypertrophic or 
dilated cardiomyopathy associated with multi-organ disease (48).
Mitochondrial neurogastrointestinal encephalopathy (MNGIE) 
syndrome is an mtDNA depletion syndrome caused by defi-
ciency of thymidine phosphorylase, resulting in imbalances in 
mitochondrial nucleotide pools. Clinical features of MNGIE 
include progressive gastrointestinal dysmotility and cachexia, 
ptosis, ophthalmoplegia, hearing loss, demyelinating peripheral 
neuropathy, and leukoencephalopathy. Cardiac manifestations 
are usually asymptomatic ventricular hypertrophy and bundle 
branch block (49, 50).
Defects in CoQ10 biosynthesis result in primary CoQ10 defi-
ciency which is a phenotypically and genetically heterogeneous 
condition with various clinical presentations, including encepha-
lomyopathy, isolated myopathy, cerebellar ataxia, and nephrotic 
syndrome. Hypertrophic cardiomyopathy has been reported 
with mutations in genes involved in CoQ10 biosynthesis (COQ2, 
COQ4, and COQ9) (51, 52).
Barth syndrome is an X-linked disorder characterized by 
cardiomyopathy, skeletal myopathy, growth retardation, neutro-
penia, and increased urinary levels of 3-methylglutaconic acid. It 
is caused by mutations in the TAZ gene that codes for tafazzin, 
a phospholipid transacylase located in the inner mitochondrial 
membrane and plays an important role in the remodeling of 
cardiolipin. Cardiomyopathies are commonly left ventricular 
non-compaction and dilated cardiomyopathies, whereas hyper-
trophic cardiomyopathy appears to be less common. Other car-
diac manifestations of Barth syndrome are arrhythmia (including 
supraventricular and ventricular tachycardia) and sudden death 
(53, 54).
Barth syndrome is one of a small group of disorders character-
ized by 3-methylglutaconic aciduria as a discriminative feature, 
where excretion of 3-methylglutaconic acid is significant and 
consistent. Other disorders in this group that might be associ-
ated with cardiomyopathy are caused by mutations in DNAJC19, 
TMEM70, and AGK (55). 3-Methylglutaconic aciduria associ-
ated with DNAJC19 mutations (dilated cardiomyopathy and 
ataxia syndrome), results from deficient mitochondrial protein 
import and is characterized by dilated cardiomyopathy or left 
ventricular non-compaction, non-progressive cerebellar ataxia, 
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This assessment is usually carried out on skeletal muscle, skin 
fibroblast, or liver tissue (11). Mitochondrial function can also 
be assessed using the extracellular flux analyzer, Seahorse instru-
ment, which can simultaneously measure mitochondrial respira-
tion and glycolysis (62). Cardiac muscle biopsy is more invasive 
and can be performed in a patient with rapid disease progression 
or when biochemical testing in fibroblasts and skeletal muscle 
and molecular testing have not led to a conclusive diagnosis (29).
Molecular testing includes assessment of mtDNA content 
and DNA sequencing. Increased mtDNA content suggests a 
compensatory mechanism due to deficient mitochondrial 
function, whereas reduced mtDNA content implies defects 
in mtDNA biosynthesis, leading to mtDNA depletion. 
Measurement of mtDNA copy number is performed by real-
time quantitative polymerase chain reaction using a mtDNA 
probe and a unique nuclear gene reference (63). Variable 
DNA sequencing options are available. If the clinical features 
of a mitochondrial disease are consistent with a recognizable 
syndrome, the mtDNA or nDNA gene known to be responsible 
for that syndrome can be tested to confirm the diagnosis. If a 
maternally inherited mitochondrial disease is suspected, the 
whole mtDNA can be sequenced. When genetically heteroge-
neous nDNA gene-related mitochondrial disease (e.g., mtDNA 
depletion syndromes) panel tests that include the known genes 
associated with such disease can be helpful. Next-generation 
massively parallel sequencing, which allows simultaneous 
sequencing of multiple genes at high coverage and low cost, 
has been widely used method for these gene panels. When 
the clinical picture is not consistent with a disease related to 
a specific gene or group of genes, a more extensive panel that 
includes all the known nDNA-related mitochondrial genes 
or whole exome or genome sequencing methodology can be 
considered (64, 65).
Currently, there are no satisfactory therapies available for 
mitochondrial disorders. Treatment remains largely sympto-
matic and does not significantly alter the course of the disease. 
Several cofactor supplementations have been tried with limited 
data supporting their benefits for most of them (6). So far, the 
only mitochondrial cardiomyopathies with an effective and spe-
cific metabolic treatment are those caused by CoQ10 deficiency. 
CoQ10 (ubiquinone) supplementation for patients with CoQ10 
deficiency results in restoring the electron flow and a dramatic 
improvement in clinical manifestations associated with CoQ10 
deficiency (66).
Heart transplantation was reported to be performed in 14% of 
patients with Barth syndrome (53). With respect to other mito-
chondrial diseases, although multi-organ diseases are considered 
a relative contraindication for solid organ transplantation, heart 
transplantation might be successful when clinical expression is 
limited to the myocardium or manifestations outside the heart 
are mild and appear non-progressive (29).
Ongoing clinical trials for potential treatment of mitochon-
drial diseases include the use of Bendavia, a mitochondrial 
permeability transition pore inhibitor, RTA 408, a potent 
activator of Nrf2 which is a regulator of cellular resistance to 
oxidants, and cysteamine bitartrate, an antioxidant (67) (http://
Clinicaltrials.gov).
testicular dysgenesis, and growth failure (56). Mutations in 
TMEM70 (mitochondrial complex V deficiency), encoding a 
protein involved in the insertion of ATP synthase (complex 
V) into the mitochondrial membrane, result in multi-organ 
mitochondrial disease with hypertrophic cardiomyopathy (57). 
Sengers syndrome, caused by mutations in AGK, might also be 
accompanied by 3-methylglutaconic aciduria and is character-
ized by hypertrophic cardiomyopathy, cataracts, myopathy, 
exercise intolerance, and lactic acidosis. The AGK gene product 
is an acylglycerol kinase and is involved in the assembly of ANT1, 
a mitochondrial adenine nucleotide transporter (58).
Friedreich ataxia is an autosomal recessive neurodegenerative 
disorder caused by mutations of FXN, which encodes frataxin, a 
mitochondrial iron-binding protein involved in the synthesis of 
the Fe–S clusters required by the ETC complexes. The clinical 
presentation includes progressive ataxia after the teenage years, 
dysarthria, loss of lower limb reflexes, peripheral sensory 
neuropathy, and diabetes mellitus. The cardiac manifestations 
include hypertrophic cardiomyopathy (59, 60).
DiAGNOSiS AND MANAGeMeNT OF 
MiTOCHONDRiAL CARDiOMYOPATHieS
The diagnosis of mitochondrial diseases is based on clinical 
recognition, biochemical screening, histopathological studies, 
functional assays, and molecular genetic testing. Due to the 
multi-organ involvement in the majority of mitochondrial 
diseases, evaluation of these diseases should include a systematic 
screening for all the targeted organs, e.g., neuroimaging, hearing 
assessment, ophthalmologic examination, liver function test, 
and serum creatinine phosphokinase (2). Biochemical screening 
tests for mitochondrial disorders include the determination of 
plasma lactate, blood glucose, urine organic acids, and plasma 
amino acids. Although lactic acidemia is a common biochemical 
feature of many mitochondrial disorders, it is neither specific 
nor sensitive (61). Hypoglycemia can be seen in children with 
mitochondrial diseases and urine organic acid analysis can show 
non-specific findings, including elevated lactate, ketone bodies, 
and TCA intermediates. A plasma amino acid profile may show 
elevation in plasma alanine level which reflects lactic acidemia 
and branched-chain amino acids which are catabolized in mito-
chondria (18).
Analysis of a fresh skeletal muscle biopsy is considered the 
gold standard in the diagnosis of mitochondrial disorders. The 
histology of affected muscles typically shows ragged-red fibers, 
which can be demonstrated using the modified Gomori trichrome 
stains, and contains peripheral and intermyofibrillar accumula-
tion of abnormal mitochondria. Examining the muscle under an 
electron microscopy can demonstrate mitochondrial prolifera-
tion and abnormal mitochondrial morphology in mitochondrial 
myopathies. Histochemical staining for different ETC complexes 
can be used to estimate the severity and heterogeneity of ETC 
complexes deficiencies in the muscle tissue (3). Mitochondrial 
function can be assessed by measuring the enzymatic activity 
of different ETC complexes using a spectrophotometric meth-
odology that utilizes specific electron acceptors and donors. 
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CONCLUSiON
Hypertrophic, dilated, non-compaction, and histiocytoid car-
diomyopathies can be the only feature or part of multi-organ 
mitochondrial diseases. Cardiomyopathies occur in approxi-
mately one-third of children with mitochondrial diseases and 
increase the mortality in these children. Therefore, screening 
for cardiomyopathy is a standard part of the management of 
individuals with known or suspected mitochondrial disease. 
Diagnosing mitochondrial diseases remains challenging in many 
cases and treatment remains largely symptomatic, as there are no 
satisfactory therapies available that significantly alter the course 
of the disease. Therefore, a lot of work is still need to be done 
to facilitate early diagnosis through discovering new disease 
biomarkers and novels genes involved in mitochondrial function 
and to find new treatment strategies that can restore the mito-
chondrial function.
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